Telomir Pharmaceuticals' Age Reversal Pill Shows Promising Results in Senior Dogs

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a company focused on longevity science, announced that its novel small molecule, Telomir-1, showcased promising "age reversal" outcomes in two senior dogs. The results were featured in an exclusive segment by ABC7, highlighting the significant health improvements in these dogs.

Under the observation of Dr. Michael Roizen, former Chief Wellness Officer of the Cleveland Clinic, a compassionate use program revealed remarkable health and vitality improvements in the dogs treated with Telomir-1. Notably, Zeus, a 12-year-old German Shepherd, experienced the remission of terminal cancer, while Benson, a 12-year-old Newfoundland with severe arthritis, regained mobility.

Telomir's newly appointed Chairman CEO, Erez Aminov, emphasized the company's commitment to advancing Telomir-1's research and bringing the treatment to human trials. Dr. Roizen added that Telomir-1 could potentially reverse several aspects of aging by lengthening telomeres and promoting cell regeneration.